Mucocutaneous leishmaniasis in an 11-year-old girl with ataxia telangectasia Á case report L eishmaniasis is a protozoal disease caused by flagellates of the genus Leishmania and transmitted by sand fly. The reservoir hosts are humans, dogs, and rodents. It has three different morphological forms: cutaneous, mucocutaneous (MCL), and visceral. The different clinical presentations depend on the interaction between parasite species of leishmania and the genetic and immunological status of the host (1).
Treatment with sodium stibogluconate 20 mg/kg/day was administered for 28 days with amphotericin 1 mg/kg. Improvement was only partial, and the patient relapsed once treatment discontinued.
Discussion
Diagnosis of leishmaniasis is based on criteria that consider epidemiological data, clinical features, and laboratory test results: direct smear, culture and inoculation, biopsy, and PCR (2) . Based on the clinical picture, the immune state of our patient and the geographical area she came from Á Ghaser Libya from where many cases of cutaneous leishmaniasis had been reported Á a clinicoepidemiological link was made and MCL was considered as a possible diagnosis, and it was confirmed by demonstrating the leishmania parasites. MCL is considered to be a disease of the New World; it is almost exclusively restricted to South America and is caused typically by Leishmania braziliensis. In rare cases, it may be caused by Old World species like L. aethiopica, L. major, and L. tropica (3, 4) .
MCL due to L. infantum had been reported in Mediterranean countries, largely resulting from HIV co-infection (3). Unfortunately, leishmania species identification was not possible in our patient as it was not available.
The nasal mucosa is the most affected area, lesions may be found on the lips, palate, pharynx, and larynx (5), and in advanced disease progressive tissue destruction and marked disfigurement may occur (3, 4) . MCL requires prolonged parenteral treatment with pentavalent antimonials or amphotericin B (2, 5). An increase in treatment failure has been documented in several regions of the world (2, 3, 6 ). The prognosis of our patient was poor because of late diagnosis, mucosal involvement, as well as the presence of underlying primary immune deficiency disease.
Unfamiliarity with the manifestations of MCL caused a delay in the diagnosis in our patient who has a primary immune deficiency disease, with consequent spreading to adjacent skin and mucosa and with inadequate response to anti-leishmania medications. Well-modulated T-cell response is needed for resolution of cutaneous lesions, whereas inadequate cellular immunity may cause uncontrolled spread of the parasite and often more severe clinical forms (6) . In addition, a preserved host immune system is required for a good therapeutic response of leishmaniasis, since it is caused by an intracellular parasite, and the antimonial would act only as an immunomodulator (2) .
Conclusion
This case is important from a diagnostic point of view because of its resemblance to other destructing granulomatous lesions of the nose as tuberculosis. To the best of our knowledge, no such case of mucocutaneous leishmaniasis has been documented previously in ataxia telangectasia as a primary immune deficiency disease. Also, the 11-year-old's case is the first case of mucocutaneous leishmaniasis reported from Libya that not only merits documentation but also mandates further research into the epidemiology, geographic distribution, and interspecies interactions of the leishmania parasite. Fig. 3 . Amastigotes inside macrophage in Leishman's stained smear. Fig. 4 . Amastigotes were evident by Giemsa stained histopathology (high power).
